Ontology highlight
ABSTRACT:
SUBMITTER: Shillingford JM
PROVIDER: S-EPMC2831854 | biostudies-other | 2010 Mar
REPOSITORIES: biostudies-other
Shillingford Jonathan M JM Piontek Klaus B KB Germino Gregory G GG Weimbs Thomas T
Journal of the American Society of Nephrology : JASN 20100114 3
Aberrant activation of the mammalian target of rapamycin (mTOR) pathway occurs in polycystic kidney disease (PKD). mTOR inhibitors, such as rapamycin, are highly effective in several rodent models of PKD, but these models result from mutations in genes other than Pkd1 and Pkd2, which are the primary genes responsible for human autosomal dominant PKD. To address this limitation, we tested the efficacy of rapamycin in a mouse model that results from conditional inactivation of Pkd1. Mosaic deletio ...[more]